Skip to main content
. 2014 Oct 30;13(20):3202–3206. doi: 10.4161/15384101.2014.950132

Figure 2.

Figure 2.

Mutant p53 is suppressed by proteasome inhibitors. (A–C) MDA-MB-231 breast, MIA PaCa-2 pancreatic and DU145 prostate cancer cells were treated with the indicated concentrations of proteasome inhibitors MG132, bortezomib (Bor), carfilzomib (Car) or thiostrepton (Thio). Immunoblot analysis of HDM2, p53, p21 and β-actin as the loading control was carried out after treatment.